Emerging Predictive Biomarkers of Immunotherapy Sensitivity in Patients with Non-Small Cell Lung Cancer - PubMed
6 hours ago
- #immunotherapy biomarkers
- #predictive oncology
- #non-small cell lung cancer
- PD-L1 expression and tumor mutation burden (TMB) are established predictive biomarkers but need improved predictive ability.
- Emerging biomarkers include genomic alterations (e.g., KEAP1, STK11, SMARCA4), metabolic pathway markers (IDO, adenosine axis), tumor-infiltrating lymphocytes, and blood-based biomarkers.
- Host factors like tobacco exposure history and body mass index influence immunotherapy outcomes.
- Artificial intelligence and machine learning enable integration of multidimensional data, creating predictive scoring systems that outperform conventional biomarkers.